Patents by Inventor Ross W. Stephens

Ross W. Stephens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER
    Publication number: 20110060529
    Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
    Type: Application
    Filed: August 30, 2010
    Publication date: March 10, 2011
    Applicant: RIGSHOSPITALET
    Inventors: Mads Holten-Andersen, Ross W. Stephens, Hans Jørgen Nielsen, Ib Jarle Christensen, Nils Brünner
  • Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker
    Patent number: 7108983
    Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: September 19, 2006
    Assignee: Rigshospitalet
    Inventors: Mads N. Holten-Andersen, Ross W. Stephens, Hans Jorgen Nielsen, Ib Jarle Christensen, Nils Brünner
  • Urokinase-type plasminogen activator receptor
    Publication number: 20030027981
    Abstract: A polypeptide presenting an epitope cross-reactive with an epitope of urokinase-type plasminogen activator receptor, and/or having uPA binding activity, is described.
    Type: Application
    Filed: January 8, 2001
    Publication date: February 6, 2003
    Inventors: Keld Dano, Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, Wolf-Dieter Schleuning, Niels Behrendt, Ebbe Ronne, Peter Kristensen, Jari Pollanen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk Moller, Vincent Ellis, Leif Roge Lund, Michael Ploug, Charles Pyke, Laszlo Patthy
  • Urokinase-type plasminogen activator receptor
    Patent number: 6248712
    Abstract: Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: June 19, 2001
    Assignee: Cancerforskningsfondet af 1989
    Inventors: Keld Danø, Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, W.D. Schleuning, Niels Behrendt, Ebbe Rønne, Peter Kristensen, Jari Pöllänen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk Møller, Vincent Ellis, Leif Røge Lund, Michael Ploug, Charles Pyke, Lászl{acute over (o )} Patthy
  • Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
    Patent number: 5891664
    Abstract: Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: April 6, 1999
    Assignee: Cancerforskningsfondet af 1989
    Inventors: Keld Dan.o slashed., Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, Wolf-Dieter Schleuning, Niels Behrendt, Ebbe R.o slashed.nne, Peter Kristensen, Jari Pollanen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk M.o slashed.ller, Vincent Ellis, Leif R.o slashed.ge Lund, Michael Ploug, Charles Pyke, Laszlo Patthy
  • Human PAI-2
    Patent number: 5422090
    Abstract: Minactivin (also known as Plasminogen Activator Inhibitor-2 [PAI-2]), a protein inactivator of urokinase-type plasminogen activator, has been shown to be a natural inactivator of this plasminogen activator which is associated with invasive tumors, and is therefore indicated as a crucial element in the body's normal defense against tumor invasion and metastasis. It may be produced by the cultivation of minactivin-producing cells in vitro, and recovery of the cell culture supernatant. By controlling the culture conditions, the protein minactivin may be produced in a partially purified form which may be used for diagnosis and treatment of tumors. The specification discloses purification of biologically active native minactivin, as well as peptides derived from minactivin and their amino acid sequences.
    Type: Grant
    Filed: July 15, 1992
    Date of Patent: June 6, 1995
    Assignees: Biotechnology Australia, Pty., Ltd., Australian National University
    Inventors: Ross W. Stephens, Jeffrey P. Golder, Toni M. Antalis, Thomas M. Barnes, Michell A. Clark, Peter L. Devine, Neil H. Goss, Philip R. Lehrbach